Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
DRMAW DERMATA THERAPEUTICS INC C/WTS (TO PUR COM)
0.0500.0000.00%
Trading Session
02/02 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
0.050
Volume
0.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Dermata Announces Topline Results From DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
- Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints -- DMT310 produced no serious adverse events related to treatment -- Dermata
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 -- Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 -SAN DIEGO, CA / ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Dermata completes a $5.0 million private placement financing in April 2022DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 /
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Dermata completes a $5.0 million private placement financingDMT310 Phase 2 rosacea trial topline results expected in H2 2022SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc. (NASD
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of
Dermata Therapeutics Reports Securities Purchase Deal With Single Institutional Investor To Buy ~$5M In Common Stock Priced At The Market
Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, to
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatmen
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023DMT310 Phase 3
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the develop
Company Overview
More
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.
CEO： Mr. Gerald T. Proehl
Market： NASDAQ
Listing Date： 08/13/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet